Aurora’s C$26.5M Safari Flower Deal Is About Germany, Australia, and Poland — Not Canada

The acquisition of Safari Flower Company adds EU GMP-certified capacity in Ontario — but the real customer is a continent away.

By Caleb Quinn

Aurora Cannabis announced Tuesday it has acquired Safari Flower Company, an EU GMP-certified cultivator and manufacturer based in Ontario, for C$26.5 million in a mix of cash and stock. The headline price is notable; the subtext is more interesting.

This deal has nothing to do with the Canadian recreational market. Aurora (NASDAQ: ACB) is buying a 59,000-square-foot indoor cultivation and manufacturing facility — not for Canadian consumers, but to produce EU GMP-certified flower it can ship to Germany, Australia, Poland, and the United Kingdom. That geographic list is the thesis.

The Structure

Aurora paid a total of C$26.5 million in aggregate consideration for 100% of Safari Flower’s shares. At closing, the company issued 2,417,180 common shares to the seller and paid C$15 million in cash, with an additional C$2 million contingent on unspecified conditions being met.

For a company Aurora’s size — it reported C$80.9 million in net revenue for Q2 fiscal 2026 — C$26.5 million is a meaningful but not extravagant commitment. The deal is structured to be “accretive,” with positive adjusted EBITDA contributions expected in fiscal 2027 and incremental gains in 2028 as the facility is fully integrated into Aurora’s supply network.

That EBITDA timeline matters. Aurora isn’t buying revenue today; it’s buying capacity for tomorrow’s export orders.

Why EU GMP Is the Asset

EU GMP certification — compliance with the European Union’s Good Manufacturing Practice standards — is a regulatory moat. It’s not easy to get, not fast to obtain, and it’s a prerequisite for legally supplying cannabis to the German prescription market, Australia’s Therapeutic Goods Administration-regulated system, and other high-margin international channels.

Safari Flower Company already has it. That’s the real value here.

Aurora has been methodically building EU GMP capacity for years. It has GMP-certified facilities in Canada and Germany, and its brands — Pedanios and IndiMed among them — are established in the European medical market. The Safari acquisition gives it more certified throughput without waiting years for a greenfield facility to earn the same credentials.

“The acquisition of Safari Flower Company marks an important milestone for Aurora as we continue to purposefully invest in expanding our EU GMP capacity to support the rapidly growing international medical cannabis market,” said CEO Miguel Martin in the announcement.

“Rapidly growing” is doing real work in that sentence. German cannabis spending has accelerated since the country’s partial legalization framework took hold, and prescription cannabis demand in Australia and Poland continues to climb. These markets pay per-gram prices that domestic Canadian operators can only dream about.

The Domestic Canadian Math

Read this deal through the lens of what it isn’t, and the strategy sharpens further.

The Canadian recreational market has spent the last three years grinding operators down with price compression, oversupply, and margin erosion. Aurora was badly burned in the early post-legalization years — it took impairments measured in billions of dollars and spent years restructuring. The company that emerges has been deliberately redirecting away from domestic volume battles and toward premium international medical markets.

Safari Flower’s Ontario location is a practical choice — proximity to Aurora’s existing cultivation sites reduces logistics friction — but the output is earmarked for export. The facility won’t be competing for shelf space at a Toronto pot shop. It’ll be producing flower that lands in German pharmacies, where patients pay on a per-gram basis and governments cover costs through prescription reimbursement.

That’s a structurally different business from Canadian cannabis retail.

Where This Fits the M&A Picture

Aurora’s deal arrives at an interesting moment for cannabis M&A broadly. Domestically, operators are limping through price compression and regulatory stasis, and deal activity has been largely defensive — consolidation plays by distressed sellers, not strategic acquirers writing checks.

The international medical angle is a different category. Companies with genuine EU GMP infrastructure are relatively scarce, and the gap between EU-certified and non-certified producers is widening as markets like Germany mature. Aurora is paying C$26.5 million for certified capacity that a competitor would need two to three years and an uncertain regulatory process to replicate.

Meanwhile, the Glass House–Vireo joint venture announced Sunday is a distinctly American story — two operators combining California retail exposure to survive a brutal market. Aurora’s move reads differently: it’s a profitable Canadian exporter buying more production to feed growing markets that most U.S. operators can’t legally touch.

What to Watch

The C$2 million contingency payment suggests there are conditions attached — likely tied to regulatory approvals or facility performance milestones — but Aurora has not specified. The EBITDA-positive timeline of fiscal 2027 (which runs through May 2027 for Aurora) gives the company roughly a year to integrate and optimize before investors expect financial contribution.

Analysts covering ACB will be looking at two things: whether Aurora can maintain its international revenue growth trajectory with the added capacity, and whether the share-based component of the deal — 2.4 million shares — creates meaningful dilution at current trading levels.

Aurora shares trade on both the NASDAQ and TSX under the symbol ACB.

The Safari Flower deal won’t transform Aurora’s balance sheet overnight. But it reinforces a deliberate positioning: Aurora is building a global medical cannabis supply chain at a moment when its largest international markets are still expanding. That’s a different game from the one most Canadian — and virtually all American — cannabis operators are playing.

Caleb Quinn covers cannabis markets, MSOs, and capital allocation for CannabisInquirer.com.